文献速递艾滋病与性传播感染

急性HIV感染期间启动基于依非韦伦和多替拉韦的抗逆转录病毒治疗后的免疫学、认知和精神学结局

Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection.
PubMed 文献 · Clin Infect Dis · 2023-01-01

这项回顾性分析纳入258例急性HIV-1感染参与者,分别启动基于依非韦伦(n=131)、基于多替拉韦(n=92)或多替拉韦联合马拉维若强化(n=35)的方案并维持96周。与依非韦伦组相比,多替拉韦组第96周CD4+和CD8+ T细胞计数增量更大,NPZ-4改善更明显,抑郁和痛苦症状相似。

要点

  • 急性HIV感染期启动基于多替拉韦方案96周,CD4+和CD8+ T细胞计数增量大于基于依非韦伦方案。
  • 第96周NPZ-4认知改善多替拉韦组优于依非韦伦组,第24周两组相似。
  • 两组随访期间基于问卷的抑郁情绪和痛苦症状相似。

核心结论

  • 在急性HIV感染个体中,基于多替拉韦的96周抗逆转录病毒治疗与更大的CD4+和CD8+ T细胞计数增量及认知表现改善相关。

研究设计与样本

  • 回顾性分析纳入258例急性HIV-1感染参与者,启动基于依非韦伦(n=131)、基于多替拉韦(n=92)或多替拉韦联合马拉维若强化(n=35)的方案,均含2种核苷类逆转录酶抑制剂并维持96周。

主要发现

  • 基线中位年龄26岁,99%为男性,36%在Fiebig I-II期入组。
  • 第24周和第96周血浆病毒抑制在各组间相似。
  • 与依非韦伦组相比,多替拉韦组第96周CD4+ T细胞计数增量更大(P < .001),CD8+ T细胞计数增量更大(P = .015),CD4/CD8比值增量相似。
  • NPZ-4改善第24周两组相似,第96周多替拉韦组更明显(P = .005)。
  • 基于患者健康问卷和痛苦温度计的抑郁情绪和痛苦症状随访期间两组相似;多替拉韦联合马拉维若组结果与多替拉韦组相比依非韦伦组的结果相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Efavirenz (EFV)- and dolutegravir (DTG)-based antiretroviral therapy (ART) is the former and current recommended regimen for treatment-naive individuals with human immunodeficiency virus type 1 (HIV-1). Whether they impact the immunological and neuropsychiatric profile differentially remains unclear. METHODS: This retrospective analysis included 258 participants enrolled during acute HIV-1 infection (AHI). Participants initiated 1 of 3 ART regimens during AHI: EFV-based (n = 131), DTG-based (n = 92), or DTG intensified with maraviroc (DTG/MVC, n = 35). All regimens included 2 nucleoside reverse-transcriptase inhibitors and were maintained for 96 weeks. CD4+ and CD8+ T-cell counts, mood symptoms, and composite score on a 4-test neuropsychological battery (NPZ-4) were compared. RESULTS: At baseline, the median age was 26 years, 99% were male, and 36% were enrolled during Fiebig stage I-II. Plasma viral suppression at weeks 24 and 96 was similar between the groups. Compared with the EFV group, the DTG group showed greater increments of CD4+ (P < .001) and CD8+ (P = .015) T-cell counts but a similar increment of CD4/CD8 ratio at week 96. NPZ-4 improvement was similar between the 2 groups at week 24 but greater in the DTG group at week 96 (P = .005). Depressive mood and distress symptoms based on the Patient Health Questionnaire and distress thermometer were similar between the 2 groups at follow-up. Findings for the DTG/MVC group were comparable to those for the DTG group vs the EFV group. CONCLUSIONS: Among individuals with AHI, 96 weeks of DTG-based ART was associated with greater increments of CD4+ and CD8+ T-cell counts and improvement in cognitive performance.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chan P, Yoon B, Colby D, et al. Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection. Clin Infect Dis. 2023. PMID: 35687498. doi:10.1093/cid/ciac466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。